In bladder cancer, POLD1’s stabilization of MYC suggests that MYC inhibitors (e.g., KJ-Pyr-9) could disrupt this axis, while miR-155 agonists might suppress POLD1 expression by downregulating FOXO3a, reducing replication fidelity in tumor cells (16, 72). The gene discussed is MYC; the disease is urinary bladder carcinoma.